Amrutanjan Health Care Limited has issued a comprehensive response to a surveillance query from the National Stock Exchange of India regarding a news article and court order, clarifying the company's position on recent developments.

NSE Surveillance Query Response

The company addressed three specific queries raised by NSE in its letter dated 17 March 2026. In response to questions about potential negotiations or events, Amrutanjan Health Care clarified that no such negotiations were taking place. The news item referenced in the NSE letter pertains to an old case titled Writ Petition No. 35484 of 2005, which has now been decided by the Hon'ble Madras High Court.

Court Order Details

The company received the copy of the court order late on 17 March 2026. As required under SEBI regulations, Amrutanjan Health Care provided detailed information about the legal proceedings in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Legal Case Information

Business Impact Assessment

The company has emphasized that the court decision will not impact its business and operations. Key points regarding the impact include:

• The matter has been disclosed as contingent liability in annual reports
• No material impact on financial or operational activities
• Company maintains regular compliance with disclosure requirements
• News articles contain certain factually incorrect information

Regulatory Compliance

Amrutanjan Health Care confirmed its commitment to regulatory compliance, stating that the company is regular and prompt in providing information to exchanges. The response was signed by Gagan Preet Singh, General Manager - Legal, Company Secretary & Compliance Officer, and digitally authenticated on 18 March 2026.

The company is actively evaluating the matters and reserves its right to pursue all available legal remedies, both regarding the case outcome and news articles containing incorrect information. The company has affirmed its full commitment to complying with all applicable regulatory requirements and will continue taking necessary steps to ensure adherence.

Amrutanjan Health Care Limited has reported its financial results for the third quarter, showing mixed performance across operational metrics. The company's EBITDA increased to ₹252M compared to ₹234M in the same period last year, while the EBITDA margin declined to 17.85% from 19.02% year-over-year.

Financial Performance Overview

The latest quarterly results demonstrate steady EBITDA growth despite margin compression. The healthcare company achieved revenue growth to ₹1.4B from ₹1.22B, with net profit reaching ₹195M compared to ₹192M in the previous year.

Operational Analysis

While the company achieved EBITDA growth in absolute terms, the margin compression indicates increased operational costs relative to revenue growth. The EBITDA margin decreased by 117 basis points, reflecting challenges in maintaining profitability ratios despite revenue expansion.

Board Meeting and Corporate Actions

As previously announced, the company's Board of Directors convened on February 3, 2026, through video conferencing to review these financial results and consider the second interim dividend for FY 2025-26. The meeting was conducted in accordance with Regulation 29(1) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Regulatory Compliance

The company maintained proper trading window restrictions during the results announcement period, with the closure effective from January 1, 2026, to February 5, 2026. This compliance measure aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, ensuring market integrity during financial disclosure periods.